<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00615667</url>
  </required_header>
  <id_info>
    <org_study_id>SYSU-PRGNS-001</org_study_id>
    <nct_id>NCT00615667</nct_id>
  </id_info>
  <brief_title>Prospective, Multicenter Study of the Efficacy and Tolerance of Tacrolimus on Refractory Nephrotic Syndrome (RNS)</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Exploring the efficacy and safety of Tacrolimus on refractory nephrotic syndrome ; Acquiring
      the experience of Tacrolimus on the treatment of refractory nephrotic syndrome in Chinese
      patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2006</start_date>
  <completion_date type="Actual">September 2008</completion_date>
  <primary_completion_date type="Actual">September 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Remission rate</measure>
    <time_frame>2006-2008</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Renal function, proteinuria, relapse</measure>
    <time_frame>2006-2008</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">61</enrollment>
  <condition>Kidney Diseases</condition>
  <condition>Nephrotic Syndrome</condition>
  <condition>Tacrolimus</condition>
  <arm_group>
    <arm_group_label>tacrolimus(fk506) treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>tacrolimus(fk506) treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tacrolimus (FK506)</intervention_name>
    <description>Started: 0.05-0.1mg/kg/d,divided into two daily dose at 12hr; the blood level:5-10ng/ml in induction phase;and 4-6ng/ml in maintenance phase;</description>
    <arm_group_label>tacrolimus(fk506) treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects of either sex, 14-65 years of age;

          2. Diagnosis of Nephrotic syndrome with hypoalbuminemia (&lt;3.0g/dl) and heavy proteinuria
             (&gt; 3.5g/24hr);

          3. Provision of written informed consent by subject or guardian;

          4. Refractory nephrotic syndrome:

        Steroid resistant: Persistence of proteinuria despite prednisone therapy 1mg/kg/d for 16
        weeks; Steroid dependent: NS recurs when steroid dosage decease.Twice within 6 months, and
        3 times within 1 year.

        Exclusion Criteria:

          1. Inability or unwillingness to provide written informed consent ;

          2. Known hypersensitivity or contraindication to tacrolimus, cyclophosphamide,
             azathioprine, corticosteroids;

          3. Usage of immunosuppression therapy (MMF, CTX, CysA, MTX ect) for more than 1 week
             within 1 month prior to first randomization;

          4. Pregnancy, nursing or use of a non-reliable method of contraception;

          5. Continuous dialysis starting more than 2 weeks before randomization into the induction
             phase and/or continuous dialysis with an anticipated duration of more than 8 weeks;

          6. Previous kidney transplant or planted transplant;

          7. Scr &gt; 4mg/dl (353umol/L);

          8. Active hepatitis, with liver dysfunction;

          9. Diagnosed DM;

         10. Participation in another clinic trial and/or receipt of investigational drugs within 4
             weeks prior to screening .
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xueqing Yu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Nephrology, 1st Affiliated Hospital, Sun Yat-Sen University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ping Fu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Nephrology, West China Hospital of Sichuan University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yunhua Liao, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Nephrology, 1st Affiliated Hospital of Guangxi Medical University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jin li Zhang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of nephrology, People's Hospital of Yunnan Province</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jian Chen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Nephrology, Fuzhou Military General Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tanqi Lou, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Nephrology, 3rd Affiliated Hospital of Sun Yet-Sen University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yaozhong Kong, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Nephrology, 1st People's Hospital of Foshan</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Junzhou Fu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Nephrology,1st People's Hospital of Guangzhou</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Wei Shi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Nephrology, People's Hospital Guangdong Provincial</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Zhengrong Liu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Nephrology, Nanfang Hospital of Southern Medical University</affiliation>
  </overall_official>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 1, 2008</study_first_submitted>
  <study_first_submitted_qc>February 1, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 14, 2008</study_first_posted>
  <last_update_submitted>April 19, 2016</last_update_submitted>
  <last_update_submitted_qc>April 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 20, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Xue Qing Yu</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Refractory Nephrotic syndrome</keyword>
  <keyword>Tacrolimus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Nephrotic Syndrome</mesh_term>
    <mesh_term>Nephrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

